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Objectives. We performed a systematic literature review to analyze the clinical application and the safety of mifepristone,
a prominent antiprogesterone agent, in meningioma patients. Materials and Methods. A systematic search was performed
through Medline, Cochrane, and clinicaltrials.gov databases from 1960 to 2014. Study Selection. Studies were selected through
a PICO approach. Population was meningioma patients, meningioma cells cultures, and animal models. Intervention was
mifepristone administration. Control was placebo administration or any other drug tested. Outcomes were clinical and radiological
responsiveness, safety profile, and cell growth inhibition. Results. A total of 7 preclinical and 6 clinical studies and one abstract were
included. Encouraging results were found in preclinical studies. Concerning clinical studies, the response rate to mifepristone
in terms of radiological regression and symptomatic improvement/stability in patients with inoperable meningioma was low.
In meningiomatosis, favorable preliminary results were recorded. The safety profile was good. Limitations were as follows. The
tumoral expression of progesterone receptors was not analyzed systematically in every study considered. Conclusions. No clear
evidence exists to recommend mifepristone in inoperable meningiomas. Preliminary encouraging results were found in diffuse
meningiomatosis. Mifepristone is a well-tolerated treatment. Patients’ selection and hormonal profile analysis in meningiomas are
fundamental for a better understanding of its benefit. Multicenter placebo-controlled trials are required.
1. Introduction
Meningiomas represent the most common primary intracra-
nial neoplasm, with an annual incidence of 7-8 cases/100000
individuals [1]. Surgery represents the first line of treatment
for symptomatic or growingmeningiomas and the recurrence
rate is proportional to the extent of resection [2]. Gross total
resectionmay be challengingwith lesions located near critical
neurovascular structures or highly infiltrating the bone or
the dura. Technical advances in microsurgical techniques,
endoscopic approaches, and radiation therapies, especially
radiosurgery, have recently improved the management of
recurrent meningiomas.
Epidemiological studies have reported a higher preva-
lence of meningioma in females [1] and further studies
showed a positive association between meningioma and
breast cancer with a twofold increase in risk [3]. Similarly,
waxing and waning of clinical manifestations during preg-
nancy,more evident during the last fourmonths of gestations,
were observed [4, 5].These observations led to the hypothesis
that meningioma growth may be hormonally affected or
dependent.
Donnell et al. [6] first described estrogen receptor (ER)
expression inmeningioma specimens. Further histochemical
staining has shown how, contrarily to breast cancer cells,
meningioma cells present a high expression of progesterone
receptors (PR) and only a weak positivity for ER [7–9].
In most progesterone receptor positive tissues, estrogens
modulate the presence of PR [10] but this seems not to be
the case for meningiomas. PR were found also in normal
leptomeningeal tissue and they may influence the normal
functioning of the meninges [11].
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Many hormonal antagonists have been used for antineo-
plastic purpose. Mifepristone (RU-486) was a French dis-
covery in 1982 and it has been used as a drug to terminate
early pregnancy. It is an oral progesterone antagonist with a
minor affinity for the glucocorticoid receptor [12]. Given its
different hormonal and endocrine properties, a number of
clinical trials started to investigate its alternative applications
in the oncologic field [13–21]. The aim of this paper is to
perform a systematic review of the literature regarding the
oncological use of mifepristone in meningiomas, to clarify its
clinical indications and the long-term safety.
2. Materials and Methods
The literature search was performed by one of the authors
(Giulia Cossu) through the electronic databases Medline and
Cochrane from January 1960 till December 2014, using the
search terms “mifepristone” and “meningioma,” as free text.
We also manually reviewed the reference lists of identified
studies and scanned abstracts from recent (from 2001 to 2015)
conference proceedings. Finally, we searched for ongoing
trials on https://clinicaltrials.gov/.
2.1. Study Selection. Two authors (Giulia Cossu and Mah-
moud Messerer) reviewed independently full-text articles,
abstracts, and citations to select pertinent studies. Search
was focused on the usefulness of mifepristone treatment and
treatment related side effects in patients with meningiomas:
the study selection was based on a PICO approach. Pop-
ulation included patients with a diagnosis of meningioma,
both confirmed histologically and suspected by radiological
characteristics. Interventionwasmifepristone administration
and the control was represented by the administration of
placebo or another drug. The primary outcomes considered
were the radiological response (diminution or stabilization of
tumor volume assessed through serial CT or MRI) and the
clinical improvement, either subjectively declared from the
patients or objectively assessed through a medical examina-
tion, evaluated during and/or after treatment administration.
The secondary outcomes evaluated were the clinical toler-
ance and the side effects related to mifepristone treatment.
Randomized controlled trials were preferred but also full-text
articles of retrospective or prospective studies evaluating the
efficacy or the feasibility of mifepristone treatment in menin-
giomas were included. Preclinical studies, using cell cultures
or animal models, were also considered. Considering the
paucity of literature data on the topic, we decided to include
case reports and case series when satisfying clinical and
radiological evaluations were present. Abstract and posters
reporting unpublished data were included. Review studies
and studies not in English were not further considered.
In case of disagreement about the inclusion of a study,
this was discussed and considered eligible only if a consensus
from all the examiners was reached.
3. Results
With our literature search, 67 articles were identified and
screened on the basis of title and abstract. Two abstracts were
also considered pertinent to the topic.
A total of 7 preclinical and 6 clinical studies and one
abstract were included in our systematic review (Figure 1,
flow chart).
3.1. Preclinical Studies (Table 1). In 1986, Olson et al. [22] first
demonstrated the efficacy of mifepristone in inhibiting cell
growth in three cultures of human meningioma cells after 28
days of treatment.Thehistological gradewas not specified but
all the specimens were positive for PR and weakly positive
for ER. Mifepristone seemed to compete with progesterone
for the progesterone-binding protein site inmeningioma cells
with an inhibition of cell growth ranging between 18 and 36%.
A clear dose effect was seen only in one of three specimens,
thus indicating that a competitive binding may not be solely
responsible for these results [22].
Blankenstein et al. [23] reported similar results in 30
cultures of human meningioma cells exposed to estrogen,
progesterone, tamoxifen, and mifepristone at variable con-
centrations for 8 days. Cell growth was significantly reduced
by mifepristone exposure (𝑝 < 0.05) when compared to
control cultures.
According to Koper et al. [24], progesterone and mifepri-
stone may modulate the sensibility of meningioma cells to
the epidermal growth factor (EGF): culture cells treated with
mifepristone showed in fact a diminished response to the
mitogenic effect of EGF. However, the PR expression was
not analyzed in one case and the EGF receptors (EGFR)
expression was not specified in 2 cases.
Schrell et al. [25] showed no effect from progesterone or
mifepristone exposition in 23 meningioma cell cultures with
varying degrees of PR expression.The thymidine-labeled up-
take was unaffected by progestogenic treatment and the DNA
polymerase activity was not correlated with the PR expres-
sion. Analogously, Wilisch-Neumann et al. [26] reported
a very limited response from mifepristone treatment: the
growth inhibition was evident in one of four analyzed
specimens and the concentration of mifepristone needed was
too elevated to be used in common clinical practice.
Matsuda et al. [27] showed interesting results: they
conducted an in vitro study associated with an in vivo
evaluation after implantation of tumoral cells in the subrenal
capsule of nude mice. Mifepristone showed a cytostatic and
a cytocidal effect independently from PR expression in vitro.
In fact, over 9 specimens not expressing PR, 7 responded to
treatment. Similar results were found in the animal model,
where an inhibition of tumor growth was independent of PR
expression in the meningioma cells implanted.
Olson et al. [28] used 6 nude mice to perform a placebo-
controlled study.They obtained satisfying results with regres-
sion of the volume of the implanted meningioma in two of
three cases, and only a small amount of cells was found in the
third case receiving mifepristone.
In vitro and preclinical studies supported thus the realiza-
tion of clinical trials to evaluate the efficacy ofmifepristone in
patients with unresectable meningioma.
3.2. Clinical Trials in Meningioma Patients (Table 2). All
included full-text studies were retrospective. Five studies
evaluated the effect of mifepristone therapy on the clinical
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67 articles identified
with the terms
“mifepristone” and
“meningioma” as free
text
33 articles excluded:
(i) 24 not pertinent/repetition
(ii) 9 not in English
34 articles screened
on title and abstract
22 articles excluded:
(i) 20 reviews articles
(ii) 2 articles with insufficient radiological/
clinical data
13 full-text articles
included
7 preclinical
6 clinical studies
1 full-text related
article assessed
for eligibility
2 abstracts identified
with the terms
“mifepristone” and
“meningioma” in
conference
proceedings 2011–15
1 abstract excluded:
(i) Repetition of a full-text article
1 abstract included
Figure 1: Flow chart.
and radiological follow-up of meningioma patients [29–33].
One study focused on the evaluation of side effects of long-
term mifepristone treatment [34]. All the studies considered
focused on patients with unresectable or recurrent menin-
giomas, with progression at clinical or radiological follow-up
in most of the cases, with the exception of the study of Touat
et al. [33], which was conducted on three patients with diffuse
meningiomatosis.
The abstract included reported preliminary results of a
phase III double-blind randomized placebo-controlled study
conducted in patients with unresectable meningiomas [35].
The dose of 200mg/day was chosen to obtain a good
antiprogesterone effect without a significant antiglucocorti-
coid activity [36, 37]. The duration of the treatment varied
among the studies from 2 to 31 months, and the follow-up
period extended from the duration of the treatment to 14
years. To avoid adrenal insufficiencymost authors introduced
a substitutive treatment of dexamethasone during the first
weeks or during the whole length of the treatment [29–32].
3.2.1. Therapeutic Effects. Grunberg et al. reported prelimi-
nary results in 14 patients in 1991 [29]. Thirteen patients were
evaluated for the clinical and radiological follow-up and in
5 of the 13 patients (38%) tumor regression was recorded,
accompanied by a subjective symptomatic improvement in
3 of them (23%). Three patients experienced progression
(23%) and two of them had malignant meningioma. Daily
oral mifepristone for a period of 2 years or more was well
tolerated.
Given these encouraging results, the same group started
a phase III randomized double-blind placebo-controlled trial
on the usefulness of mifepristone treatment on 160 patients
with progressive meningiomas. An abstract was presented
in 2001 and authors failed to demonstrate improvement
in freedom from progression in mifepristone group (𝑝 =
0.44) [35]. However hormone receptors expression was not
specified. These results were never further published.
Grunberg et al. reported in 2006 more detailed results
in 28 patients, including the patients previously enrolled in
the study of 1991 [30]. The mean follow-up was 35 months.
A radiological improvement with reduction in tumor size
was reported in 5 of the 28 patients (17%) and a clinical
improvement was evident in 3 patients out of 28 (11%). Seven
of 8 patients experimenting regression (both clinical and
radiological) were males or premenopausal females.
Lamberts et al. [31] evaluated a cohort of 10 patients
with 12 recurrent or inoperable meningiomas, progressing
at follow-up. They recorded a transient regression in 33%
of the tumors (4/12) with further radiological progression
after the discontinuation of the treatment. The disease was
stable in 25% cases (3/12), while 42% (5/12) progressed. Fifty
percent of the patients (5/10) reported clinical improvement,
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objectively assessed in 2 cases. No data about PR expression
were provided.
De Keizer and Smit [32] reported a case series of 2
patients treated with long-termmifepristone for unresectable
sphenoid-ridge meningioma, with a follow-up of 14 years.
Both patients experienced radiological stability and sympto-
matic improvement: one reported an improvement in visual
acuity and the other experienced regression of his headache
with no changes in visual acuity. Both patients progressed
and deteriorated after treatment discontinuation with a new
stabilization after the restarting of the treatment.
Touat et al. [33] enrolled three postmenopausal patients
with diffuse meningiomatosis. The histological examination
was performed only in one case. All the patients experi-
mented long-lasting clinical remission and in two of them
meningiomas stabilized or diminished in size after mifepri-
stone treatment.
3.2.2. Side Effects. The most common described side effect
of mifepristone therapy is asthenia. Severe fatigue however
is rare. Some patients experienced anorexia, vomiting, and
nausea [29, 34]. All these symptoms may be attributed to
the blockade of glucocorticoid receptors and an improvement
of these manifestations with an exogenous corticosteroid
treatment was described [29, 31]. The majority of the studies
supplemented patients under mifepristone treatment with
daily low-dose of dexamethasone, at least for the first two
weeks or for the whole duration of the treatment.
Hot flashes, gynecomastia or breast tenderness, decreased
libido, and cutaneous rashwere also observed [29].The cessa-
tion of menses was an expected side effect in premenopausal
patients, with a return to a normal menstrual cycle after
a variable period of time after the discontinuation of the
treatment [29]. Supplementation in testosterone helped in
normalizing libido in male patients [29]. Mifepristone treat-
ment was associated with the development of endometrial
hyperplasia [30, 32, 34, 35].
One case of peritoneal adenocarcinoma [30] and one case
of benign ovarian serous cystadenoma [33] were reported.
The association with mifepristone treatment is unknown.
Subclinical hypothyroidism was observed [38] and some
authors reported transient elevation of hepatic enzymes dur-
ing mifepristone treatment for other conditions [39, 40] but
this finding was not confirmed by Spitz et al. in meningioma
patients [34].
4. Discussion
Meningiomas have a significant association with hormone-
dependent conditions [3, 4, 41] and since the discovery of the
high prevalence of PR expression inmeningiomas, the option
to use hormonal therapy as cytostatic agent became a real
therapeutic strategy.
Mifepristone is a 19-norsteroid agent presenting a high
affinity for the PR and a lower but considerable affinity for
the glucocorticoid receptor [12]. The abortifacient properties
of mifepristone were early discovered and the use of this drug
is currently approved for early termination of pregnancy,
cervical dilatation for surgical abortion, and management
of early embryonic loss [42]. Further applications to the
endocrine and oncological fields remain under investigation.
The expression of PR in meningioma cells was early
characterized in 1979 [6] and, since then, different hormonal
therapies have been used in preclinical studies and clinical
trials.Most of them showed contrasting results [43–48], while
initial encouraging results were found for mifepristone in in
vitro studies and animal models.
Clinical studies on the efficacy of the use of mifepristone
in meningiomas showed contrasting results. Grunberg et al.
[29] in their study of 1991 reported positive results in 38%
patients with inoperable meningiomas. A further enrollment
allowed the same group to publish more extensive data: in
2006, the authors failed to show new cases of radiological or
clinical response tomifepristone treatment [30]. Analogously
in 2001 they presented in an abstract the results of a placebo-
controlled RCT in patients with unresectable meningiomas:
no significant difference on freedom from progression was
observed between the two arms [35]. Unfortunately, limited
data are available for this trial.
Lamberts et al. [31] showed a stable disease or a transient
regression in tumor volume in 58% of cases (7/12 menin-
giomas), but when the time course of tumor size (volumetric
data) was analyzed in more details, the results were no more
convincing. The four tumors decreasing in size showed a
progressive reduction of tumor volume only in one case
during mifepristone treatment, while in two cases a transient
precocious regressionwas followed by a dimensional increase
duringmifepristone treatment. In one case, an initial stability
was followed by a slight reduction of tumor volume at one
year of treatment.
De Keizer and Smit [32] showed a radiological stability
and a symptomatic improvement in both patients studied,
having an unresectable sphenoid-ridge meningioma.
Two case reports, not included in the primary analysis
because of the lacking of precise radiological data, confirmed
a radiological and clinical stability with long-term mifepri-
stone treatment in two patients [49, 50] and a decrease in
tumor size in one case [50].
Long-term treatment with mifepristone is generally well
tolerated. Adrenal insufficiency may be seen with very high
doses of mifepristone, where the compensatory elevation
of endogenous cortisol becomes insufficient, but in most
of cases the introduction of a low-dose therapy of daily
dexamethasone per os was sufficient to relieve the mild
symptoms of corticotropic insufficiency (asthenia, nausea,
and vomiting) [30, 31].
Mifepristone treatment was associated with the develop-
ment of endometrial hyperplasia [30, 32, 34] and endome-
trial polyps [49]. The hormonal pathways determining this
phenomenon are still unknown. Heikinheimoab et al. [38]
investigated the effects of long-term mifepristone treatment
(200mg/d for at least 15 months) on sex steroids and
gonadotrophins levels. A prolonged treatment is associated
with increased serum levels of androstenedione, testosterone,
estrone, and estradiol, probably through the inhibition of glu-
cocorticoid receptors. An increase in cortisol level secondary
to mifepristone administration may be in fact associated
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with an increase in adrenal production of androgens with a
secondary aromatization to estrogens [38, 51, 52].The prolife-
rative effects of estrogens are in these cases no more counter-
acted by progesterone.
The case of subclinical hypothyroidism recorded [38]
was probably linked to an interaction with the corticotropic
axis [53, 54] or due to an effect on synthesis and/or release
of thyroxine (biologically characterized by an elevation of
thyroid-stimulating hormone and a decrease in thyroxin)
rather than a direct interaction of mifepristone with the
thyroxine receptor [55].
In conclusion, mifepristone seems to act on the proges-
terone, glucocorticoid, androgen, and thyroid pathways on
the long term.
From our literature analysis only retrospective studies
were identified and included as full-text articles. One RCT
was only available as abstract. Thus, no class I evidence may
be extrapolated. Also two case series, respectively, of 2 [32]
and 3 patients [33] were included. The experience in clinical
practice is very limited and the major evidence derives from
one single center [29, 30, 35].
The studies were extremely heterogeneous both in the
preclinical and in the clinical groups, in terms of population
included, duration of treatment, and length of follow-up. For
all these reasons, a meta-analysis was not performed.
In clinical studies, a heterogeneous cohort of patients in
terms of sex, menopausal status, histology, and expression of
PR was enrolled and data were pooled together in the major-
ity of cases. Furthermore, some authors included cases with
no histologic diagnosis [29, 30] and the specific expression of
PR was not analyzed in most of cases [29–31, 33].
The selection of the population of interest may be deter-
minant: Grunberg et al. [30] observed significant responses
in males and in premenopausal women, and further studies
focusing on this population may help in detecting clini-
cally significant responses deriving form mifepristone treat-
ment.
The histology and the WHO grade may be important in
determining the response to mifepristone treatment. A lower
presence of PRwas noted in anaplasticmeningiomas [56] and
PR expression was inversely correlated with Ki67 expression
and WHO grading [57, 58]. Thus, mifepristone may not be a
good treatment for anaplastic and malignant meningiomas.
Encouraging results support the use of mifepristone in a
clinical trial for patients with diffuse meningiomatosis. Touat
et al. [33] enrolled three patients and all showed a long-lasting
clinical improvement during the treatment, associated with
two cases with a radiological shrinking or stabilization. From
epidemiological studies, it is evident that diffuse menin-
giomatosis is characterized by a more pronounced female
predominance and immunohistochemical studies showed
a higher PR expression in this subgroup of meningiomas
[59].
Progesterone receptors exist as two isoforms (PRA and
PRB) codified from the same gene by different promoters
[60]. Increasing literature evidence shows how they have dif-
ferent functions [61, 62] and PRA seems to be downregulated
in models of antiprogestin resistant breast cancers [63, 64].
Mifepristone showed a major action in preclinical models
of breast cancers overexpressing PRA when compared to
cancers having a high PRB expression [65].These effects may
be useful in guiding the choice of target patients and it would
be interesting to analyze more in details the relationship
between the PR isoforms expressed and the responsiveness
to mifepristone treatment in meningioma patients.
Some authors support the hypothesis that the antitu-
moral effect of mifepristone may not depend directly on
the expression of PR [66]. Koper et al. [24] showed how
progesterone may act in vitro through the modulation of the
cellular response to variousmitogenic stimuli as EGF, insulin,
and insulin-like growth factor 1 (IGF-1).Mifepristone inhibits
growth induced by EGF in vitro [24] and it may block the
activation of IGF-1 signaling in some breast cancer cell lines
[67]. These may be additional mechanisms of action of this
drug. Furthermore, mifepristone inhibited cell migration,
abnormal adhesion to basement membrane, and angiogen-
esis in an animal model of adenocarcinoma [68]. Thereafter,
it was shown to promote apoptosis through the activation of
the pathway of caspase-3 [18]. Further investigations should
be conducted to study the interactions between mifepristone
and its modulations of signal transduction pathways.
Further limitations of the studies included in this review
are related to the volumetric assessment of tumor size, which
was not recorded systematically by all the authors, and the
radiological techniques varied between CT scan and MRI,
even in the same studies. Indeed, a well-performed MRI
is more sensible in detecting minimal changes in size than
a simple CT evaluation. Also, the length of the treatment
and the follow-up period should be sufficiently long to
detect minimal volumetric changes; the effects of a hormonal
therapy may in fact be evident after a certain period of time,
because of the slow proliferation rate of meningioma cells.
Furthermore, clinical improvement should be objectively
documented when possible (periodical neurological exami-
nation of cranial nerve palsies, ophthalmological evaluation
for visual acuity and visual fields, etc.).
Through the analysis of the literature, only minor evi-
dences exist to recommend mifepristone treatment in sur-
gically inoperable progressing meningiomas. This hormonal
therapy has a safe profile and a good clinical tolerance, but
the clinical benefit is very limited and it should be recom-
mended only in an experimental setting. The indications for
diffuse meningiomatosis are still preliminary. Well-designed
multicentered placebo-controlled trails with a long follow-
up should be realized to finally determine the real value of
mifepristone treatment.
Mifepristone may represent a starting point towards new
perspectives: other hormonal therapies and in particular
other progesterone antagonists with higher affinity for PR
may represent a real future alternative. Furthermore advances
in molecular and genomic studies are actually targeting the
molecular changes in tumorigenic mechanisms to obtain
more selective therapies. Inhibitors of EGFR or PDGFR may
inhibit meningioma growth but preliminary studies failed to
show a clinical benefit [69, 70]. Less selective tyrosine kinase
receptor inhibitors, like sunitinib, may be more promising
[70, 71]. Also antiangiogenetic molecules may represent a
valuable option [72].
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5. Conclusions
The recurrence rate is high for meningiomas incompletely
resected and different therapeutic options were explored for
the management of recurrent or inoperable meningiomas.
The characterization of hormonal receptors, in particular PR,
opened new ways towards antiprogestogens as therapeutic
strategies.
According to literature analysis no clear evidence exists to
recommend mifepristone treatment in recurrent and inop-
erable meningiomas. A possible application may be found
in diffuse meningiomatosis but further confirmations are
needed. Mifepristone is a well-tolerated treatment; however
a preliminary selection of the patients is fundamental.
It is time the clinical experience available from single
center studies is substituted by well-designed multicenter
placebo-controlled studies.
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